First, we tested the anti-tumor effects of the anti-CTLA-4 Ab in mouse models of bladder cancer (MB49), breast cancer (EMT6), colorectal cancer (CT26WT), and liver cancer (Hepa1-6). Here, CTLA4 is linked to neoplasm.